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Abstract
AIM
To determine the significance and need for investigation 
of incidental prostatic uptake in men undergoing 
18F-labelled fluorodeoxyglucose (18F-FDG) positron 
emission tomography/computed tomography (PET/CT) 
for other indications.
METHODS
Hospital databases were searched over a 5-year period 
for patients undergoing both PET/CT and prostate 
magnetic resonance imaging (MRI). For the initial 
analysis, the prostate was divided into six sectors and 
suspicious or malignant sectors were identified using 
MRI and histopathology reports respectively. Maximum 
and mean 18F-FDG standardised uptake values were 
measured in each sector by an investigator blinded 
to the MRI and histopathology findings. Two age-
matched controls were selected per case. Results were 
analysed using a paired t-test and one-way ANOVA. 
For the second analysis, PET/CT reports were searched 
for prostatic uptake reported incidentally and these 
patients were followed up. 
RESULTS
Over a 5-year period, 15 patients underwent both PET/
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CT and MRI and had biopsy-proven prostate cancer. 
Malignant prostatic sectors had a trend to higher 
18F-FDG uptake than benign sectors, however this was 
neither clinically nor statistically significant (3.13 ± 
0.58 vs  2.86 ± 0.68, P  > 0.05). 18F-FDG uptake showed 
no correlation with the presence or histopathological 
grade of tumour. 18F-FDG uptake in cases with prostate 
cancer was comparable to that from age-matched 
controls. Forty-six (1.6%) of 2846 PET/CTs over a 
5-year period reported incidental prostatic uptake. Of 
these, 18 (0.6%) were investigated by PSA, 9 (0.3%) 
were referred to urology, with 3 (0.1%) undergoing 
MRI and/or biopsy. No cases of prostate cancer were 
diagnosed in patients with incidental 18F-FDG uptake in 
our institute over a 5-year period. 
CONCLUSION
18F-FDG uptake overlaps significantly between malignant 
and benign prostatic conditions. Subsequent patient 
management was not affected by the reporting of 
incidental focal prostatic uptake in this cohort. 
Key words: 18F-labelled fluorodeoxyglucose; Positron 
emission tomography reporting; Positron emission 
tomography/computed tomography; Prostate cancer; 
Magnetic resonance imaging
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: 18F-labelled fluorodeoxyglucose (18F-FDG) 
uptake overlaps significantly between malignant and 
benign prostatic conditions. In a cohort of nearly 
3000 patients over a 5-year period, the reporting of 
incidental elevated prostatic 18F-FDG uptake did not 
affect subsequent clinical management or patient 
outcomes. 
Chetan MR, Barrett T, Gallagher FA. Clinical significance of 
prostate 18F-labelled fluorodeoxyglucose uptake on positron 
emission tomography/computed tomography: A five-year review. 
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INTRODUCTION
Positron emission tomography of 18F-labelled 
fluorodeoxyglucose uptake combined with computed 
tomography (18F-FDG PET/CT) is a mainstay of 
oncologic imaging. PET/CT imaging is well-tolerated 
and therefore has become a powerful tool for 
the diagnosis, staging and monitoring of many 
metabolically-active cancers. However, 18F-FDG PET/CT 
imaging is not routinely used for detecting prostate 
cancer for both biological and technical reasons. 
Firstly, glucose uptake in well-differentiated prostatic 
adenocarcinoma is less avid than in many other 
cancers due to low glycolytic activity[1]. Secondly, 
urinary excretion of 18F-FDG in the bladder and urethra 
can mask pathological uptake in the adjacent prostate. 
Thirdly, there is a large overlap in 18F-FDG uptake 
between malignant disease, benign hyperplasia and 
inflammation of the prostate[1].
In men undergoing 18F-FDG PET/CT for unrelated 
reasons, incidental prostatic uptake is found in 
0.6%-2.8% of studies[1-5]. Although this is a small 
percentage of cases, it affects a large number of 
men given the growing number of PET/CT studies 
performed per year: 50000 annually in the UK 
and 2 million annually in the United States[6,7]. The 
significance of such incidental uptake, together with 
the need for further investigation, is both uncertain 
and controversial. 
A previous meta-analysis of prostatic uptake on 
18F-FDG PET/CT imaging showed that PET/CT cannot 
reliably differentiate benign from malignant disease, 
although only a small percentage of these patients 
underwent a definitive biopsy[8]. The published 
positive predictive value of 18F-FDG uptake for 
detecting prostate cancer ranges between 30% (in 
a low-risk population of men with bladder cancer 
undergoing radical prostatectomy) to 65% [in a high-
risk population of men undergoing prostate magnetic 
resonance imaging (MRI)][9,10]. Some studies argue 
that the positive predictive value is increased if 
18F-FDG uptake shows a high SUVmax, the lesion is in 
a peripheral location and the CT demonstrates a lack 
of calcification[11-13]. However, these features all show 
considerable overlap between malignant and benign 
disease.
Serum prostate-specific antigen (PSA), multiparametric 
prostate magnetic resonance imaging (mpMRI) and 
prostate biopsy can be used to investigate incidental 
prostatic 18F-FDG uptake to determine if the patient 
has significant prostate cancer[5,9]. However, there is 
no consensus on the management of patients with 
incidental prostatic 18F-FDG uptake[9].
In order to better understand the significance of 
incidental prostatic 18F-FDG uptake, we investigated 
both the correlation of prostatic 18F-FDG uptake with 
findings from MRI and histopathology, and the impact 
on patient management of reporting increased 18F-FDG 
uptake in the prostate. 
MATERIALS AND METHODS
Study design and patient population 
This single-institution retrospective study was approved 
locally, with the need for informed consent for data 
analysis waived. The hospital radiology database was 
searched to identify a total of 2846 18F-FDG PET/CT 
studies performed on male patients in the period 
January 2010 to September 2015. For the first part 
of the study, 23 eligible men were identified who had 
both a prostate MRI and an 18F-FDG PET/CT study. 
15 of these men had prostate adenocarcinoma on 
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ultrasound-guided biopsy or MRI/ultrasound fusion 
biopsy. Five men were excluded (the prostate cancer 
was treated prior to undergoing PET/CT in 4 patients, 
and one patient had > 4 years between MRI and 
PET/CT). For the second part of the study, the 18F-FDG 
PET/CT reports were searched to identify patients with 
incidentally reported focal prostatic 18F-FDG uptake. 
Patient records were examined for details of follow-
up investigations and management. Two cases were 
included in both the first and second parts of the study. 
MRI and 18F-FDG PET/CT analysis
A proprietary workstation and software (Volume 
Viewer, Advantage Workstation, GE Healthcare, 
Milwaukee, WI, United States) were used to review the 
18F-FDG PET/CT images. The prostate was divided into 
six sectors: Left and right sides at the apex, mid-zone 
and base of the gland. Standardised uptake values 
(SUV) in each sector were measured by an investigator 
who was blinded to the MRI and histopathological 
findings. A threshold of 75% of the SUVmax was used to 
calculate the SUVmean[14].
MRI reports were used to identify the prostatic 
sectors that were suspicious for tumour. Histopathology 
reports were used to identify the prostatic lobe(s) in 
which cancer had been detected. Sectorial analysis 
could not be performed for patients with no tumour 
focus on MRI, or bilateral tumour on histopathology 
(Figure 1).
Age-matched controls undergoing 18F-FDG PET/CT 
but without prostate cancer were randomly selected 
for each case from PET/CT studies recently undertaken 
in the department; two controls for each case were 
acquired. Age matching within 18 mo was used as the 
criterion, and patients with a known tumour close to 
the prostate were excluded. 
Statistical analysis
A paired two-tailed student’s t-test was used to compare 
the 18F-FDG uptake within suspicious or malignant 
sectors, with that in the remaining prostate for each 
individual patient. A paired two-tailed student’s t-test 
was also used to compare prostatic 18F-FDG uptake 
in patients with that from the controls. A one-way 
ANOVA was used to compare prostatic 18F-FDG uptake 
between histopathological subgroups. Statistical 
analyses were performed using GraphPad Prism 
version 6.00 (GraphPad Software, La Jolla, CA, United 
States). 
RESULTS
Eighteen patients who had both 18F-FDG PET/CT and 
prostate MRI studies were included in the first part of 
the study. The median age was 72 years, median PSA 
was 7.30 ng/mL and median time difference between 
the 18F-FDG PET/CT and the prostate MRI was 11.5 
mo. See Table 1 for patient characteristics. 
There was a trend for a higher 18F-FDG uptake in 
prostatic sectors shown to be suspicious on MRI or 
4
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MRI-normal region MRI-suspicious region
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Figure 2  Sectorial analysis comparing 18F-labelled fluorodeoxyglucose 
uptake in sectors found to be suspicious on magnetic resonance imaging 
or malignant on histopathology with 18F-labelled fluorodeoxyglucose 
uptake in the remaining sectors. Mean values and standard deviations have 
been shown. 
 Figure 1  Flowchart showing inclusion and exclusion criteria for selection of cases for sector-based analysis.
Male patients who had both prostate MRI and 18F-FDG PET/CT 
n  = 23
Time delay > 4 yr between PET/
CT and MRI studies
Excluded 
n  = 1
Brachytherapy prior to PET/CT (n  = 2)
Radical prostatectomy prior to PET/CT (n = 2)
Excluded 
n  = 4
Sectorial analysis of 18F-FDG 
uptake based on MRI findings 
n  = 10
Sectorial analysis was not performed as 
MRI showed no focus of tumour
n  = 8
Biopsy was not performed due 
to reassuring MRI
Excluded 
n  = 4
Excluded 
n  = 4
TRUS or MRI/TRUS fusion biopsy showed 
benign tissue or high grade PIN
TRUS or MRI/TRUS fusion biopsy showed prostate 
adenocarcinoma
n = 10
Sectorial analysis of 18F-FDG 
uptake based on histopathology 
n  = 8
Sectorial analysis was not 
performed as histopathology 
showed tumour bilaterally
n  = 2
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malignant on histopathology, compared to those in the 
remainder of the prostate, but this was not statistically 
significant (Figure 2). There was no significant 
difference in 18F-FDG uptake between cases with 
prostate cancer and age-matched controls undergoing 
PET/CT who did not have prostate cancer. Patients 
were classified into the following subgroups according 
to histopathology findings: biopsy not performed (n = 
4), benign biopsy or high-grade prostatic intraepithelial 
neoplasia (PIN) (n = 4), low-grade prostate cancer 
with Gleason score ≤ 3 + 4 (n = 6), and high-grade 
prostate cancer with Gleason score ≥ 4 + 3 (n = 4). 
18F-FDG uptake was not significantly different between 
subgroups; we therefore found no correlation between 
prostatic 18F-FDG uptake and the presence or grade of 
tumour confirmed on histopathology. Figure 3 illustrates 
a representative case of a 70-year-old man with high-
grade prostate cancer that showed no uptake on PET/
CT. See Table 2 for mean values of SUVmax and SUVmean 
derived from sectorial, case-control and subgroup 
analysis. 
For the second part of the study, 2846 male 
patients undergoing 18F-FDG PET/CT over a 5-year 
period were followed-up. 46 men (1.6%) had an 
Age 
(yr)
MRI before or after 
PET/CT?
18F-FDG PET/CT 
indication
Prostate 
SUVmax
Prostate MRI indication MRI result PSA 
(ng/mL)
Biopsy result
73 2 mo before Bone metastases 
(prostate primary)
3.4 Negative TRUS biopsy T2aNxMx 20.8 Gleason 4 + 5 = 9
72 11 mo after Non-Hodgkin 
lymphoma
2.7 Elevated PSA, negative 
TRUS biopsy
T2aNxMx 8.8 Gleason 5 + 3 = 8
62 3 mo after Cancer of unknown 
primary
3.9 Prostate cancer staging T3bNxMx 37 Gleason 4 + 3 = 7
75 46 mo after Head and neck cancer 3.4 Active surveillance T1NxMx 2.28 Gleason 4 + 3 = 7
76 6 mo before Gastrointestinal stromal 
tumour
3 Elevated PSA, negative 
TRUS biopsy
T2bNxMx 150 Gleason 3 + 4 = 7
79 22 mo after Non-Hodgkin 
lymphoma
2.9 Elevated PSA T2aNxMx 5.4 Gleason 3 + 4 = 7
66 30 mo after Non-Hodgkin 
lymphoma
3.1 Active surveillance T2cNxMx 4.8 Gleason 3 + 4 = 7
73 26 mo after Oesophageal cancer 2.4 Active surveillance T2cNxMx 7.8 Gleason 3 + 3 = 6
68 18 mo after Cancer of unknown 
primary
3.9 Elevated PSA T2aNxMx 6.1 Gleason 3 + 3 = 6
74 5 mo before Oesophageal cancer 3.9 Elevated PSA T1NxMx 7.3 Gleason 3 + 3 = 6
68 5 mo before Hodgkin lymphoma 9.9 Elevated PSA, negative 
biopsy
No focus of tumour 4.7 High-grade PIN
65 39 mo before Colorectal cancer 5.2 Elevated PSA, negative 
TRUS biopsy
No focus of tumour 8.6 High-grade PIN
76 34 mo before Non-Hodgkin 
lymphoma
4.2 Elevated PSA Suspicious foci bilaterally 15 Benign
67 4 mo before Non-Hodgkin 
lymphoma
4.1 Incidental prostatic 
18F-FDG uptake
Suspicious foci bilaterally 5.5 Benign
72 16 mo after Pyrexia of unknown 
origin
2.7 Chronic urinary infection Likely prostatitis Not done Biopsy not 
performed
78 1 mo after Non-Hodgkin 
lymphoma
3.1 Elevated PSA No focus of tumour 11.4 Biopsy not 
performed
61 12 mo after Lung nodule 5.2 Elevated PSA, positive 
family history
No focus of tumour 4.5 Biopsy not 
performed
68 7 mo after Colorectal cancer 8.8 Incidental prostatic 
18F-FDG uptake
No focus of tumour 3 Biopsy not 
performed
Table 1 Characteristics of patients who had both 18F-labelled fluorodeoxyglucose positron emission tomography/computed 
tomography and prostate magnetic resonance imaging studies
SUV: Standardised uptake value, PSA: Prostate specific antigen, TRUS: Transrectal ultrasound.
Mean SUVmax Mean
SUVmean
Sectorial analysis
MRI - normal prostatic sectors 3.02 1.74
MRI - suspicious prostatic sectors 3.1 1.89
Histopathology - benign prostatic lobe 2.86 1.79
Histopathology - malignant prostatic 
lobe
3.13 1.82
Case-control analysis
Age-matched controls 3.09 1.83
Cases with prostate cancer 3.26 1.81
Subgroup analysis
Biopsy not performed 4.95 1.91
Benign disease and high-grade PIN 5.85 2.86
Low-grade prostate cancer (Gleason ≤ 3 
+ 4)
3.2 1.83
High-grade prostate cancer (Gleason 
score ≥ 4 + 3)
3.35 1.78
Table 2 Sectorial analysis, case-control analysis and subgroup 
analysis showed no significant difference in 18F-labelled 
fluorodeoxyglucose uptake
SUV: Standardised uptake value, PIN: Prostatic intraepithelial neoplasia. 
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incidental and unexplained finding of elevated 
prostatic 18F-FDG uptake. 18 (0.6%) of these patients 
underwent further investigation. They had a median 
age of 68 years, median prostatic SUVmax of 7.80 and 
median PSA of 3.04 ng/mL. See Table 3 for patient 
characteristics.
Of these 18 men, 9 (0.3%) were referred to urology. 
Two men had a prostate biopsy, which showed benign 
disease and high-grade PIN respectively (Figure 4). 
No cases of prostate cancer were diagnosed in the 
5-year period. See Figure 5 for more detailed clinical 
outcomes.
Age (yr) 18F-FDG PET/CT indication Prostate SUVmax PSA (ng/mL) Urology referral made Urology outcome
68 Adrenal nodule 10.4 3 Yes MRI - no suspicious foci
77 Lung nodule 4.5 2.78 Yes Biopsy - high-grade PIN
67 Non-Hodgkin lymphoma 4.5 5.5 Yes MRI - suspicious foci
Biopsy - benign
68 Colorectal cancer 5.9 3.04 Yes PSA monitoring
58 Colorectal cancer 7.6 1.38 Yes PSA monitoring
64 Non-Hodgkin lymphoma 5.4 1.84 Yes PSA monitoring
58 Non-Hodgkin lymphoma 19.9 7.44 Yes PSA monitoring
81 Cholangiocarcinoma 10.3 18 Yes Lost to follow up
75 Hepatic metastases (colorectal primary) 8 - Yes Lost to follow up
61 Colorectal cancer 14 1.47 No - PSA normal
55 Paraneoplastic syndrome 4.8 0.62 No - PSA normal
61 Non-Hodgkin lymphoma 5.8 2.85 No - PSA normal
68 Gastrointestinal stromal tumour 13.2 1.48 No - PSA normal
71 Hepatic metastases (colorectal primary) 9.2 4.9 No - palliative care
87 Oesophageal cancer 5.3 11.86 No - palliative care
82 Colorectal cancer 15.4 3.85 No - palliative care
35 Hodgkin lymphoma 11.8 3.04 No - suspected prostatitis
71 Oesophageal cancer 7.3 4.58 No - likely urethral uptake
Table 3 Characteristics of patients in whom elevated prostatic 18F-labelled fluorodeoxyglucose uptake was investigated
SUV: Standardised uptake value; PSA: Prostate specific antigen; PIN: Prostatic intraepithelial neoplasia. 
A B
C D
Figure 3  High-grade prostate cancer showing no increased uptake on positron emission tomography/computed tomography in a 73-year-old man. A, B: 
Prostate MRI performed for raised PSA (19 ng/mL) showed a high probability lesion in the right apex transition zone (arrow in A) with matching restricted diffusion 
on the ADC map (B). Subsequent targeted transperineal biopsy confirmed Gleason 4 + 5 disease in 40% of cores; C, D: PET/CT performed after a two-month 
interval and no intervening treatment showed no focal uptake in this region shown as both fused PET/CT imaging (C) and PET alone (D). PET/CT: Positron emission 
tomography/computed tomography; MRI: Magnetic resonance imaging; ADC: Apparent diffusion co-efficient; PSA: Prostate specific antigen.
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DISCUSSION
Prostate cancer is the commonest male cancer[15]. 
There is therefore a potentially high incidence of 
synchronous prostatic tumour in patients undergoing 
18F-FDG PET/CT for other indications. However, PET/CT 
lacks specificity and sensitivity for primary detection 
of prostate cancer; consequently it is unclear how 
patients with incidental tracer uptake in the prostate 
should be managed. Our study has shown that focal 
18F-FDG uptake is not indicative of prostate cancer in 
this cohort, with SUVmean and SUVmax values significantly 
overlapping between malignant and benign conditions, 
and that the reporting of incidental prostatic uptake 
A B
C D E
Figure 4  Incidental prostatic 18F-labelled fluorodeoxyglucose uptake in a 67-year-old patient with Stage Ⅳ diffuse large B-cell lymphoma. A, B: Focal 
uptake in the posterior right peripheral zone of the prostate at the level of the mid-gland as demonstrated on PET (A) and fused PET/CT (B); SUVmax = 4.5; C-E: 
Prostate MRI shows non-specific geographical intermediate signal on T2-weighted imaging (C), but with no matching restricted diffusion on b-1400 diffusion-
weighted images (D) or ADC maps (E). The MRI findings are low probability for tumour. Subsequent transrectal ultrasound-guided biopsy showed no cancer. PET/
CT: Positron emission tomography/computed tomography; MRI: Magnetic resonance imaging; ADC: Apparent diffusion co-efficient.
Figure 5  Flowchart showing clinical outcomes in patients with elevated prostatic 18F-labelled fluorodeoxyglucose uptake. 
18F-FDG PET/CT studies on male patients between Jan 2010 and Sept 2015
n  = 2846
Elevated prostatic 18F-FDG uptake reported by radiologist
n  = 76
Uptake considered to 
be urethral
Excluded 
n  = 14
Excluded 
n  = 16
Known prostate cancer 
Post-procedure, e.g.,  TURP
Known locally invasive rectal 
carcinoma
Investigation of incidental prostatic 18F-FDG uptake recommended by radiologist
n  = 46 (1.6%)
Not investigated as patient 
was ill, receiving palliative 
care or died 
n  = 28
Serum PSA measured
n  = 18
Urology referral made 
n  = 9
Urology referral not made
n  = 9
Prostate MRI alone (n  = 1) which was normal
Prostate biopsy (n  =2) which showed benign tissue or 
high grade PIN 
PSA monitoring (n  = 4)
Lost to follow up (n  = 2)
Normal PSA (n  = 4)
Began palliative care (n  = 3)
Suspected prostatitis (n  = 1)
Uptake thought to be urethral 
on review (n  = 1)
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did not affect subsequent clinical management of any 
patient in our institute over a 5-year period.
Sector-based analysis showed that, in individual 
patients, malignant prostatic sectors had a trend to 
higher 18F-FDG uptake than benign sectors. However, 
this difference was not statistically significant and 
total prostate 18F-FDG uptake in men with prostate 
cancer was comparable to that from age-matched 
controls. Comparison of 18F-FDG uptake across patient 
subgroups showed no correlation between 18F-FDG 
uptake and histopathological findings. Although some 
authors have suggested that 18F-FDG uptake weakly 
correlates with Gleason score, the small numbers in 
our study did not demonstrate this finding[9,16]. In fact, 
we observed a higher SUVmax and SUVmean in patients 
with no biopsy, benign biopsy or high grade PIN than 
in patients with prostate cancer. This may be partially 
explained by increased 18F-FDG uptake in prostatitis, 
where there is also increased glucose uptake within 
the inflammatory tissue[17].
Incidental and unexplained prostate uptake was 
found in 1.6% of all 18F-FDG PET/CT studies in male 
patients, which is comparable to the rate reported 
previously[3-5]. These patients had a median SUVmax 
of 7.8, which is suspicious for tumour; other authors 
have suggested an SUVmax greater than 6.0 should be 
considered as a cut-off value for high-grade prostate 
cancer[9]. Only 40% of patients with incidental and 
unexplained prostatic uptake were investigated 
with a serum PSA. Twenty percent of patients were 
referred to a urologist, and only one-third of these 
patients underwent further investigation with either 
biopsy or MRI. This may reflect the fact that the 
existing cancer diagnosis is the primary factor in 
determining clinical prognosis, and that the subsequent 
detection of prostate cancer would not significantly 
affect patient management due to unsuitability for 
radical therapy. Another possibility is a reluctance 
to perform a transrectal prostate biopsy in patients 
undergoing chemotherapy due to the risk of sepsis. 
In some patients, incidental prostatic uptake was not 
investigated for different reasons, e.g., uptake was 
thought to represent tracer in the urethra upon review 
(Figure 6), or uptake resolved on repeat PET/CT (Figure 
7). Ultimately over a 5-year period in our centre, 
involving nearly three thousand 18F-FDG PET/CT studies, 
no change in patient management occurred as a result 
of an incidental finding of elevated prostatic 18F-FDG 
uptake. Therefore, our retrospective study questions 
the need to investigate incidental prostatic uptake of 
18F-FDG in men undergoing PET/CT. 
Our study has some limitations. Firstly, as a 
retrospective study our population consisted of 
patients who underwent 18F-FDG PET/CT primarily for 
other malignancies, and therefore the time difference 
between PET/CT and MRI was long in some cases 
(up to 46 mo). This timescale is similar to previously 
reported retrospective studies and given that the 
natural history of prostate cancer is one of a slow-
growing tumour, most prostate cancers will be present 
for years before clinical presentation[10,18]. Secondly, 
A B
Figure 6  Midline uptake on 18F-labelled fluorodeoxyglucose positron emission tomography/computed tomography in a 71-year-old man with oesophageal 
carcinoma and serum prostate specific antigen of 4.58 ng/mL. A, B: Fused PET/CT and PET-only imaging shows focal uptake in the midline of the prostate 
(arrowed). The uptake was considered to be tracer in the urethra given its anatomical location. PET/CT: Positron emission tomography/computed tomography.
A
B
Figure 7  Resolving focal prostatic uptake in a 61-year-old man with 
Stage IV high-grade non-Hodgkin’s lymphoma and serum prostate-specific 
antigen of 2.85 ng/mL. A: Fused PET/CT imaging performed after 2 cycles of 
chemotherapy shows focal uptake (arrowed) in the left side of the prostate at 
the level of the midgland on fused PET/CT; B: Repeat PET/CT performed 4 mo 
later following completing of 6 cycles of chemotherapy demonstrates resolution 
of this focal uptake. PET/CT: Positron emission tomography/computed 
tomography.
Chetan MR et al . Clinical significance of prostate 18F-FDG uptake
357 September 28, 2017|Volume 9|Issue 9|WJR|www.wjgnet.com
the number of eligible patients in our study was small. 
Thirdly, patients in our study had ultrasound-guided 
biopsy or MRI/ultrasound fusion biopsy, which are 
less sensitive in detecting prostate cancer than whole-
mount histology derived from prostatectomy samples. 
In conclusion, 18F-FDG uptake has low clinical 
utility in distinguishing benign and malignant prostatic 
disease. Reporting incidental prostatic uptake did not 
affect subsequent patient management or clinical 
outcomes in this cohort of patients. This study 
suggests there may be little benefit in investigating 
incidental elevated prostatic 18F-FDG uptake on 
PET/CT which should be addressed with future large 
prospective studies.
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tomography/computed tomography (PET/CT) is used extensively in the 
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